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Abstract
Background: Type 2 diabetes mellitus (T2D) poses a large worldwide burden for health care systems. One possible
tool to decrease this burden is primary prevention. As it is unethical to wait until perfect data are available to
conclude whether T2D primary prevention intervention programmes are cost-effective, we need a model that
simulates the effect of prevention initiatives. Thus, the aim of this study is to investigate the long-term cost-
effectiveness of lifestyle intervention programmes for the prevention of T2D using a Markov model. As decision
makers often face difficulties in applying health economic results, we visualise our results with health economic
tools.
Methods: We use four-state Markov modelling with a probabilistic cohort analysis to calculate the cost per quality-
adjusted life year (QALY) gained. A one-year cycle length and a lifetime time horizon are applied. Best available
evidence supplies the model with data on transition probabilities between glycaemic states, mortality risks, utility
weights, and disease costs. The costs are calculated from a societal perspective. A 3% discount rate is used for
costs and QALYs. Cost-effectiveness acceptability curves are presented to assist decision makers.
Results: The model indicates that diabetes prevention interventions have the potential to be cost-effective, but the
outcome reveals a high level of uncertainty. Incremental cost-effectiveness ratios (ICERs) were negative for the
intervention, ie, the intervention leads to a cost reduction for men and women aged 30 or 50 years at initiation of
the intervention. For men and women aged 70 at initiation of the intervention, the ICER was EUR27,546/QALY
gained and EUR19,433/QALY gained, respectively. In all cases, the QALYs gained were low. Cost-effectiveness
acceptability curves show that the higher the willingness-to-pay threshold value, the higher the probability that the
intervention is cost-effective. Nonetheless, all curves are flat. The threshold value of EUR50,000/QALY gained has a
30-55% probability that the intervention is cost-effective.
Conclusions: Lifestyle interventions for primary prevention of type 2 diabetes are cost-saving for men and women
aged 30 or 50 years at the start of the intervention, and cost-effective for men and women aged 70 years.
However, there is a high degree of uncertainty around the ICERs. With the conservative approach adopted for this
model, the long-term effectiveness of the intervention could be underestimated.
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Type 2 diabetes mellitus (T2D) poses a large worldwide
burden for health care systems as its prevalence is high
and treatment expensive. The International Diabetes Fed-
eration (IDF) estimated that about 258 million people
around the world suffered from diabetes mellitus in 2010,
and the majority have T2D [1]. IDF estimates that health
care expenditures account for 11.6% of the world’st o t a l
health care expenditures [1]. Health care costs related to
T2D increases with T2D complications [2]. Furthermore,
T2D is commonly detected late in the course of disease.
The time between T2D onset and diagnosis can be up to
ten years [3]. In consequence, effective intervention pro-
grammes that address major risk factors for T2D devel-
opment, ie, lack of physical activity and unhealthy diet,
could lead to a decreased T2D prevalence, reduction in
costs due to treatment and inability to work, and shorten
the time between onset and diagnosis of disease which
may reduce complication rates.
Lifestyle interventions for prevention of T2D will need
to be evaluated. Examples of such interventions are the
Prevention of Diabetes Self-Management Program (PRE-
DIAS) [4] and the Saxon Diabetes Prevention Pro-
gramme (SDPP) which are described in more detail
below. Both target individuals at high risk of developing
T2D. The lifestyle interventions are comprised of moti-
vation analysis, exercise programmes and dietary
counseling.
Medicine and public health expect high value from
primary prevention of T2D, but not much is known
about its long-term cost-effectiveness. Saha et al [5]
recently reviewed economic evaluations of lifestyle inter-
ventions for primary and secondary prevention of dia-
betes and cardiovascular disease. They identified a range
of decision analytic models. However, only three models
include the state of normal glucose tolerance and this is
an e c e s s a r ys t a t et oa c c u r a t e l ya n a l y s et h ei m p a c to f
such interventions [6-8].
Decision modelling is an effective and relatively inex-
pensive technique for extrapolating available, evidence-
based information on the epidemiology, pathogenesis
and intervention results of a disease in order to estimate
costs and effectiveness over a longer time span [9]. Scul-
pher, Fenwick and Claxton [10] describe the role of
cost-effectiveness models as to “identify optimum treat-
ment decisions in the context of uncertainty about
future states of the world.”
Public health pioneers also discuss uncertainty. In
1992, the famous epidemiologist Geoffrey Rose wrote “It
needs to be better understood by the public, by policy-
makers, and by medical scientists alike that we can
never be certain of anything. Certainty is not a prerequi-
site for action.” [11].
Uncertainty is embedded in every result from every
study. The greater the complexity of the disease, the
higher the uncertainty in the analysis. Decision-making
under uncertainty is always a balancing act between
being timely and having data available. If ideal data (eg,
changes in mortality and morbidity) are not available,
w em u s tu s et h eb e s ta v a i l a b l ee v i d e n c et oe s t i m a t e
meaningful outcomes.
This analysis uses decision modelling to further
knowledge on primary prevention of T2D. We evaluate
the cost-effectiveness of lifestyle intervention pro-
grammes to prevent T2D. We calculate costs from a
societal perspective, ie, costs from different perspectives
are considered. The goal of this study is to provide pub-
lic health decision-makers with information that can be
used to enhance decision-making about primary preven-
tion of diabetes.
Methods
A model evaluating a hypothetical intervention pro-
gramme is used. The targetted programmes are
described below. Two examples for those programmes
in Germany are PREDIAS and SDPP. Lifestyle interven-
tions for prevention of T2D target individuals at high
risk of developing T2D. The lifestyle interventions are
comprised of motivation analysis, exercise programmes
and dietary counselling. Each intervention is proven to
be effective and are the cornerstones for successful
implementation of a lifestyle intervention programme
[12-14]. The programmes typically have prevention
managers who organise group-based interventions and
are the direct contact persons for the participants.
The interventions consist of three steps. First, high-
risk individuals are identified with an easy, fast and low-
cost screening tool. An example is the Finnish Type 2
Diabetes Risk Score (the FINDRISK). Screening tools
are distributed through community promotion and
advertising, eg, informational leaflets at health insurance
companies, primary care physician offices, and health
fairs [15]. FINDRISK is a self-administered questionnaire
using eight simple questions to estimate risk of develop-
ing T2D in the next 10 years. Questions ask for infor-
mation such as body mass index (BMI), age, and waist
circumference. Individuals with a FINDRISK final sum
score below 11 are considered low risk, receive basic
information about healthy lifestyle, and are reminded to
complete the FINDRISK questionnaire again in the
future. Those with a final sum score of 11-20 are con-
sidered high-risk and invited to join a lifestyle interven-
tion course. Individuals with a final sum score of 21 or
greater receive a recommendation to visit their general
practitioner for T2D testing. If they do not have T2D,
they are invited to join the intervention programme.
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tured programme aimed at changing lifestyle. Skilled
staff certified in T2D prevention, eg, experts in nutrition
and physical exercise and with additional education in
diabetes prevention, hold courses once a week for eight
weeks. The course consists of lectures about the physiol-
ogy of the body, healthy eating, exercise and motivation
that are given to groups of approximately ten partici-
pants. Third, participants are offered follow-up mentor-
ing, which can continue as long as they wish [16]. The
prevention manager coodinating the course is in contin-
uous contact with the participants and reminds them to
reach and maintain their goals. The participant has reg-
ular email and telephone support and receives a
monthly newsletter and quarterly journal that provide
information about aspects of a healthy lifestyle. At regu-
lar intervals, the prevention manager collects objective
measurements on participants, ie, blood pressure,
weight, and waist and hip circumferences. The lifestyle
intervention can raise awareness through personal con-
tact, the a website, journals and newspapers, personal
invitation letters, and health fairs. If an individual is
interested, he or she receives a folder with further
information.
Markov modelling with a probabilistic cohort analysis
was used to calculate the cost per QALY gained of the
above described lifestyle inte r v e n t i o ni nc o m p a r i s o nt o
no intervention.
Decision modelling for health economic evaluation in
general and further details specific to this model are
explained elsewhere [17,18].
Four health states were modelled in a cohort simula-
tion. An individual in this simulation could have normal
glucose tolerance (NGT), impaired glucose tolerance
(IGT), diagnosed type 2 diabetes mellitus (T2D), or be
dead. Figure 1 displays a schematic of the model. The
simulations were conducted with Microsoft
® Office
Excel
® 2004 for Mac.
Each state portrays aggregate values while an indivi-
dual in each state can have different complications.
We applied a one-year cycle length and a lifetime time
horizon. The lifetime time horizon indicates that indi-
viduals will be followed life-long for all possible out-
comes that might arise. The model assumes
participants only participate in the intervention for five
years and the effectiveness of the intervention lasts for
six years, with a linear decrease in effectiveness during
the six years with no effectiveness difference in the
seventh year. The Finnish DPS found that after discon-
tinuation of active counselling, the lifestyle interven-
tion group had a lower incidence of T2D after seven
years compared to the no-intervention group [19]. The
current study selects input model parameters from dif-
ferent studies as no single source could be identified
for all of the necessary data. Cost-effectiveness accept-
ability curves are used to illustrate final results to help
decision-makers. In the following, input parameters are
discussed in more detail.
Transition probabilities
Table 1 summarises the one-year transition probabilities
chosen for the model.
Figure 1 Markov Model Schematic.
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tion from IGT to T2D. However, it is important to
model from the time when a person has NGT as pre-
vention ideally starts before development of IGT and its
higher risk. Transition probabilities between NGT and
IGT were taken from a Canadian study [6]. Data on pri-
mary prevention of IGT is sparse and most models start
with the state of IGT. The study by Caro et al [6] is
unique in its calculation of one-year transition probabil-
ities between NGT and IGT. The one-year transition
probability for no intervention was 16.3% and 15.2% for
the lifestyle intervention [6]. The one-year probability of
converting from IGT to NGT was 16.2% for no inter-
vention and 17.7% for the intervention [6]. The Finnish
DPS evaluated the risk of T2D development in persons
with IGT. In the DPS, transition from IGT to T2D was
6% for no intervention and 3% for the intervention [20].
We used a probability of moving from T2D to IGT of
0.5% for both the no-intervention and intervention
groups. These assumptions are based on the knowledge
that this transition exists but seldom occurs. The transi-
tion probability in the intervention group is likely higher
than in the no-intervention group, but we took a con-
servative approach and did not assign a difference
between the groups.
T h ep r e v a l e n c eo fI G Ta m o n gt h eg e n e r a lG e r m a n
population is used as the base for the model. A popula-
tion-based study in the region of Augsburg, Germany,
found that approximately 16% of healthy individuals
developed IGT [21]. Thus, we assume that at the begin-
ning of the model 16% of individuals have IGT, 84% has
NGT and no one has T2D.
Duration of expected effects
The model takes a conservative view by setting the
effectiveness of the intervention to last only for six
years, with a linear decrease in effectiveness during the
intervention. Thus, from year 7 and onwards the same
transition probabilities are applied for both intervention
and no-intervention groups. Seven-year effectiveness
was selected because the DPS showed a 36% reduction
in relative risk of progression from IGT to T2D
between the intervention and the control group after
seven years [19]. Furthermore, the Chinese Da Qing
Diabetes Prevention Study estimated that the lifestyle
intervention group had a 51% lower incidence of dia-
betes during the active intervention period and a 43%
lower incidence over the whole 20 year period com-
pared with control participants [22]. Our model
includes people with NGT and IGT whereas the Da
Qing Diabetes Prevention Study and the DPS only
included people with IGT in their studies. We chose to
be more conservative than either of these studies and
assumed a seven-year effectiveness to be sufficiently
conservative.
Mortality
Life tables provide the mortality rates for different ages
and sexes. Eight different mortality categories, by age
and sex, are established: less than 35, 35-64, 65-74, and
75 years and over for men and women. The groups are
estimated to give appropriate categories that are rela-
tively heterogeneous between groups and homogenous
with groups in regard to mortality.
Mr[age]
Mr[age] symbolises the probability of dying in a certain
age and sex group when a person does not have T2D.
Mortality statistics were obtained from the Statistical
Office of the Federal State of Saxony [23]. The number
of those dying due to T2D (t2d2d) was subtracted from
the total number of deaths in Saxony during 2006.
T2d2d
T2d2d is the transition probability of a person with T2D
dying from T2D. In most statistical records, this is
underestimated as many death certificates do not record
T2D as the underlying cause of death [24]. We used the
percentage of all-cause deaths attributable to diabetes in
the “Europe region with very low child and adult mor-
tality” from the study by Roglic et al [25]. The all-cause
death figures were taken from mr[age] as described
above. T2d2 was age and sex dependent.
Health care cost in different states
German estimates for health care costs in different
states were used as the cost estimates of the lifestyle
programme derived from a German setting.
cNGT
cNGT is the estimation of health care costs for someone
with NGT. The CODE-2 study calculated an average
annual direct health care cost of EUR1,372 for a person
with NGT in Germany [2]. This is the average cost for
someone without diabetes who is insured by the Ger-
man statutory health insurance. As this cost was col-
lected in 1997, we calculated a 2007 equivalent based on
a formula from the Federal Statistics Office in Germany
which was adapted for health care costs [26]. The NGT
cost of EUR1,744.21 is adjusted for the difference in
purchasing power.
Table 1 Transition matrix between health states
Transition Matrix
Intervention (No-intervention) *
To
From
NGT IGT T2D
NGT 0.848 (0.837) 0.152 (0.163) -
IGT 0.177 (0.162) 0.794 (0.775) 0.03 (0.06)
T2D - 0.005 (0.005) 0.995 (0.995)
* Please refer to figure 1 for a schematic overview
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cIGT is the estimation of health care costs for someone
with IGT. Unlike cNGT, no comparable cost estimation
could be located for the annual cost for IGT. As the
three main cost states need to be comparable, the ratio
used by Palmer et al [27] that consists of 46% of dia-
betes costs, was adapted to the CODE-2 costs. The
annual cost for IGT is estimated at EUR2,696.48, ie,
46% of EUR5,861.92 (see next paragraph).
cT2D
cT2D is the estimation of health care costs for someone
with T2D. According to the Code-2 study, the average
annual cost for a diabetic patient in Germany is
EUR4,611 [2]. Adjusting for inflation, the cost for T2D
is EUR5,861.92 [26].
Cost of the Intervention Course and Follow-up Mentoring
We analysed the course of the SDPP lifestyle interven-
tion. All costs are expressed in Euros and prices are
adjusted to 2007 values. The cost of the intervention
consists of costs for screening (ie, information folders),
the course and follow-up mentoring. Other costs such
as transportation (eg, cost of driving to educational
places) are also considered.
The cost of the intervention is calculated as follows:
Screening costs consider direct costs associated with
preparation and mailing the information folder to inter-
ested individuals before they join the programme.
Course costs are comprised of the telephone hotline,
email mentoring, newsletters, journals, collection of
medical data, postage, and the time of the prevention
manager. The prevention manager’s course time is eight
hours plus one hour for each course participant. Costs
for follow-up mentoring include the telephone hotline,
email mentoring, monthly newsletters, quarterly jour-
nals, biannual collection of medical data, postage and
the prevention manager’s time. Prevention manager fol-
low-up time includes four hours for the four events
plus one hour preparation time for each, 30 minutes
per month counselling per participant, and 30 minutes
per participant biannually for collection of medical data.
Participant driving costs to educational locations were
estimated by using an average of 5 km driving distance
multiplied by the general mileage allowance for Germany.
Table 2 gives an overview of the intervention costs.
The first year costs are approximately EUR390 and the
second and subsequent years are approximately EUR190
per year.
The participants are assumed to participate in the
intervention for five years. Thus, the costs for the inter-
vention only occur for five years.
Utility weights
A study by Kontodinopoulos et al provides health utility
values for the general Greek population and for a Greek
population with T2D [28]. Table 3 shows an overview of
the utility values in that study (mean and standard
errors). The standard errors were calculated on the basis
of reported standard deviations [29].
uNGT
We assumed that the general Greek population in the
study of Kontodinopoulos et al [28] is equivalent to the
state of NGT. This assumption probably underestimates
the utility value for NGT (uNGT) as people in the gen-
eral population might have undiagnosed IGT. The utility
value was 0.772 (SE: 0.004) for men and 0.747 (SE:
0.004) for women [28].
uIGT
The utility value for IGT (uIGT) was estimated as a 1%
decrease from uNGT. Therefore, we used a utility value
of 0.764 (SE: 0.006) for men and 0.740 (SE: 0.006) for
women.
uT2D
The utility value for T2D (uT2D) was taken from the
population with T2D in the study by Kontodinopoulos
et al [28]. Men had a utility value of 0.724 (SE: 0.010)
and women had a utility value of 0.701 (SE: 0.010).
The utility value of death was zero.
We used a 3% discount rate for both costs and
QALYs [30]. We also performed sensitivity analyses for
the discount rates of 0% and 5% and effectiveness
assumptions of 3 years and 20 years.
Probabilistic modelling allows the joint effect of para-
meter uncertainty by probabilistic distribution of each
or most input parameters [31]. Table 4 summarises the
chosen statistical distributions for the model input para-
meters and provides additional background information.
Results
The model can be adjusted to display results of men
and women for different age groups. To facilitate pre-
sentation, six age-sex groups (ages 30, 50, 70 for men
and women) are described. The results of all sub-groups
for ICER, QALYs gained and costs are displayed in table
5.
For example, the ICER is negative for men aged 50 at
the start of the intervention. The difference in costs and
QALYs gained of no intervention vs. intervention for
men aged 50 is EUR52,652 vs. EUR52,308 and 13.24
QALYs gained vs. 13.27 QALYs gained.
Figure 2 summarises the simulated costs of no inter-
vention vs. intervention among women and men at dif-
ferent ages. Women have higher costs in all categories
compared to men. The intervention leads to a cost-sav-
ings in comparison to no intervention for age groups 30
and 50. This means the intervention will save money in
these age groups as fewer people will transition to
higher-risk health states. For the group aged 70 years at
the beginning of the intervention, the intervention
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For all categories, the costs decrease substantially with
age at entry.
Figure 3 compares the QALYs gained by sex and age
groups for no intervention vs. intervention. Women have
higher QALYs gained regardless of intervention group.
Individuals in the intervention also had higher QALYs
gained. The difference in QALYs gained between the
intervention and no-intervention groups is small.
Figure 4 outlines the ICERs by age, sex and interven-
tion. ICERs were negative for men and women aged 30
and 50 at the start of the intervention. ICERs were posi-
tive (men EUR27,546/QALY gained and women
EUR19,433/QALY gained) for men and women aged 70
years. The older the individual is at cohort entry, the
higher is the ICER. The ICERs are consistently lower in
women.
Figure 5 compares cost-effectiveness acceptability
(CEA) curves by age and sex groups. The CEA curve
illustrates the probability that the intervention is cost-
effective given different willingness-to-pay threshold
values [32]. The higher the selected threshold value, the
higher the probability of the intervention being cost-
effective. The curves range between a probability of
cost-effectiveness of 30% and 55% (assumed willingness-
to-pay threshold: EUR0 to EUR50,000). The slope of the
Table 2 Assumed intervention costs
Screening (per participant) EUR113.32
Mailing informational folders EUR 113.32
52 TN/244 folders = 21.3%, one folder = EUR24.15
Course (per person) EUR109.16
Phone hotline EUR3.80
Email mentoring EUR3.80
Newsletter (8 × EUR1.75) EUR14.00
Journal (2 × EUR1.68) EUR3.36
Collection of medical data (2 × EUR0.15) EUR0.30
Postage (2 × EUR0.35) EUR0.70
Prevention managers
(contact hours + preparation)
(26 h × EUR32/10 persons) EUR83.20
Follow-up mentoring
(per person per year)
EUR183.93
Phone hotline (2 × EUR3.80) EUR7.60
Email mentoring (2 × EUR3.80) EUR7.60
Newsletter (12 × EUR0.90) EUR10.80
Journal (4 × EUR1.49) EUR5.96
Collection of medical data (2 × EUR0.15) EUR0.30
Postage (4 × EUR0.35) EUR1.40
Events, 10 person group, 2 times per year (2 × EUR45/10 persons) EUR18.00
Prevention managers
(contact hours + preparation)
(41.33 × EUR32/10 persons) EUR132.27
Other costs to be considered
Driving to educational locations, one round-trip (2 × 5 km × EUR0.30/km) EUR3.00
Summary
Screening EUR113.32
Intervention, including transportation costs EUR133.16
Follow-up, including transportation costs EUR143.95
Total cost of year 1 EUR390.43
Total cost of follow-up for year 2 and each following year EUR189.93
Table 3 Overview of utilities from a Greek population
[28]
Men (SE) Women (SE)
health utility value for NGT (uNGT) 0.772 (0.004) 0.747 (0.004)
health utility value for IGT (uIGT) 0.764 (0.006) 0.740 (0.006)
health utility value for T2D (uT2D) 0.724 (0.010) 0.701 (0.010)
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show similar CEA curves. Men and women in the older
age group have a lower CEA curve. For an assumed
willingness-to-pay threshold value of EUR50,000/QALY
gained, the probability that the intervention is cost-
effective is 45-55%. The threshold value of EUR50,000/
QALY gained is arbitrary, but these graphs provide esti-
mations of the development of the probability assuming
different threshold values. The graph also allows visuali-
sation of the uncertainty of the outcome. The presented
CEA curves display an increasing probability of cost-
effectiveness with increasing threshold value [17,32,33].
Nevertheless, the slope is unusually flat.
This model is a probabilistic model. Therefore, most
input parameters are distributed according to a certain
statistical distribution and consequently reflect uncer-
tainty [31].
Sensitivity analysis
A one-way sensitivity analysis was conducted for the dis-
count rate and effectiveness of the intervention. Both
changes have an impact on the results of the intervention.
Changing the effectiveness showed a strong influence on
the final result. The higher the assumed discount rate, the
Table 4 Chosen distributions for model input parameters
Parameter
1 Deterministic value Standard Error Distribution Alpha Beta
Ngt2igt 0.163 0.037 Beta 16.28 83.72
Igt2ngt 0.162 0.037 Beta 16.23 83.77
Igt2t2d 0.062 0.024 Beta 6.23 93.77
T2d2igt 0.005 0.007 Beta 0.50 99.50
cNGT EUR1,744.21.00 EUR1,744.21 Gamma 1.00 1744.21
cIGT EUR2,696.48 EUR2,696.48 Gamma 1.00 2696.48
cT2D EUR 5,896.48 EUR5,861.92 Gamma 1.00 5861.92
Cost of intervention EUR230.03 EUR230.03 Gamma 1.00 230.03
Mean Methods of moments
uNGT, men 0.772 0.004 Beta 7067.38 2087.26
uNGT, women 0.747 0.004 Beta 7342.67 2486.87
uIGT, men 0.764 0.006 Beta 3458.69 1066.73
uIGT, women 0.740 0.006 Beta 3578.37 1260.34
uT2D, men 0.724 0.010 Beta 1400.32 533.82
uT2D, women 0.701 0.010 Beta 1422.19 606.61
1ngt2igt: probability of moving from NGT to IGT state
igt2ngt: probability of moving from IGT to NGT state
igt2t2d: probability of moving from IGT to T2D state
t2d2igt: probability of moving from T2D to IGT state
cNGT: annual health care costs for NGT
cIGT: annual health care costs for IGT
cT2D: annual health care costs for T2D
uNGT: health utility value for NGT
uIGT: health utility value for IGT
uT2D: health utility value for T2D
Table 5 Results for incremental cost-effectiveness ratio
(ICER), quality-adjusted life years (QALYs) gained and
cost by age and sex groups
ICER
Age Sex
Men Women
30 -25,164 € -31 407 €
50 -15,108 € -21,215 €
70 27,546 € 19,433 €
QALYs gained
Age Sex
Men Women Men, intervention Women, intervention
30 17.44 18.07 17.46 18.10
50 13.24 14.06 13.27 14.08
70 6.04 6.96 6.06 6.98
Cost
Age Sex
Men Women Men, intervention Women, intervention
30 76 270 € 83,277 € 75,670 € 82,587 €
50 52,652 € 59,236 € 52,308 € 58,787 €
70 20,686 € 25,611 € 21,021 € 25,849 €
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intervention is in the future. If the duration of effective-
ness is changed to 3 years, ie only effective for two years,
interventions for all age and sex groups are not cost-
effective if the assumed cost-effectiveness threshold is
EUR50,000/QALY gained. Assuming 20-year effectiveness,
all ICERs are negative and therefore cost-effective. See
table 6 for an overview of sensitivity analyses for the
Figure 2 Costs by age, sex and intervention.
Figure 3 Quality-adjusted life years (QALYs) gained by age, sex and intervention.
Neumann et al. Cost Effectiveness and Resource Allocation 2011, 9:17
http://www.resource-allocation.com/content/9/1/17
Page 8 of 13discount rates of 0% and 5% and effectiveness assumptions
of 3 years and 20 years.
In conclusion, the model indicates that diabetes pre-
vention interventions have the potential to be cost-effec-
tive and even cost-saving, if older age groups are
excluded. However, the uncertainty of the results is
high. The sensitivity analysis shows that the model is
sensitive to parameter changes.
Discussion
Principle findings
ICERs in the young and middle-age age groups (age 30
and 50) show cost-savings and are thus naturally below
the EUR50,000/QALY gained that is routinely used as
the threshold value for German health care interven-
tions [34]. However, ICERs are positive for men and
w o m e na g e d7 0a tt h es t a r to ft h ei n t e r v e n t i o n .T h i s
shows importance of the age at the intervention initia-
tion. Even though all ICERs are considered cost-effective
(below EUR50,000/QALY gained), interventions for men
and women aged 30 and 50 specifically increase QALYs
and decrease costs. ICERs for the younger age groups
are thus not only cost-effective but also cost-saving. The
C E Ac u r v e sh a v eaf l a ts l o p ea n di n d i c a t eap r o b a b i l i t y
that the intervention is cost-effective at less than or
close to 50%. They are also uncertain results. In
Figure 4 Incremental cost-effectiveness ratios (ICERs) by age and sex.
Figure 5 Cost-Effectiveness Acceptability Curves for Different Age and Sex Characteristics.
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count rate and effectiveness reveal that the model is
sensitive to changes of the programme effectiveness,
even though most parameters were distributed probabil-
istically. We chose a conservative approach in selecting
the duration of intervention effectiveness, and believe
that the intervention could be even more cost-effective/
cost-saving than suggested by the model.
The older the patient at the start of the intervention,
the lower the costs and QALYs gained. These lower
costs and QALYs gained are primarily due to older peo-
ple being closer to death.
Compared to men, women have higher costs, higher
QALYs gained and a larger savings per QALY gained in
each age group. The higher QALYs gained occur
because women have a greater benefit from prevention
of diabetes. This is reflected in differences between uti-
lity values [28] in the different states. The higher costs
arise because women live longer.
Meaning of the study
This study provides results of a Markov model with cost
per QALY gained as the final outcome using the latest
evidence. The model merges the best available evidence
but reveals shortcomings in data availability and para-
meter certainty. Further studies are needed to obtain
these data. This study is the first to estimate the costs
of a lifestyle intervention programme similar to the
SDPP. The model underlines the importance of model-
ling all of the glycaemic states (ie, NGT and IGT) prior
to diabetes rather than using only IGT. The cost-
effectiveness acceptability curves can enhance decision-
making capability by visualising uncertainty around the
deterministic results.
Strengths and Weaknesses of the Study
The study likely underestimates the health benefits that
accrue to a diabetic patient since beneficial lifestyle
changes will also reduce the incidence of other diseases.
Considering the positive impact only on diabetes under-
estimates the positive influence on overall health. The
evaluated lifestyle changes influence the risk of diabetes
and diseases such as cardiovascular disease, cancer and
other diseases and these health consequences are unac-
counted for in the model. The same is true for produc-
tion gains resulting from better health. Furthermore,
screening (known to give valuable information from the
individual’s point of view) is also ignored in our analysis.
To balance these shortcomings on the effect side, we
excluded participant time costs.
The studies used for extraction of the different input
parameters were based on different source populations,
eg, Saxon, German, Finnish and US American. This lim-
itation needs to be accepted because of the limited good
evidence for use in modelling. We intended to do this
analysis from a societal perspective, but available data
made this only partially possible.
The DPS was conducted for a shorter time period
than the current model. Thus, there are no reliable data
on how motivation and compliance evolve over a longer
period of time. On the other hand, the Chinese Da Qing
Diabetes Prevention Study estimated that lifestyle inter-
vention was effective at 20 years after the beginning of
the intervention [22].
Besides the noted weaknesses, this study has numer-
ous strengths. The CEA curves show considerable
uncertainy when moving towards the most relevant will-
ingness-to-pay threshold values. Considering just the
deterministic ICER results shows that high cost-savings
could hide the uncertainty of the results. The model is
also transparent and can be adapted to local circum-
stances. Critical appraisal of the model is essential for
future improvements. The study models the develop-
ment of pre-diabetes and diabetes. This gives important
insight into diabetes prevention and considers the possi-
bility of conversion from diabetes to IGT. Furthermore,
the analysis takes a conservative viewpoint. The partici-
pants were only able to participate in the intervention
for five years. Thus, the costs only occur for five years.
On the other hand, the effectiveness of the intervention
is set to last only for seven years, with a linear decrease
in effectivenes over the years. Furthermore, we assumed
no difference in health utility between intervention and
no intervention when they belonged to the same state.
Studies have shown that lifestyle intervention
Table 6 One-way sensitivity analyses of discount rate and
intervention effectiveness assumption
ICER (deterministic) in Euros per QALY gained
Discount rate
0% 3% 5%
Man, 30 years -34,749 -25,164 -15,736
Women, 30 years -43,831 -31,407 -20,212
Man, 50 years -23,032 -15,108 -7,738
Woman, 50 years -30,831 -21,215 -12,746
Man, 70 years 15,796 27,546 35,863
Woman, 70 years 5,935 19,443 29,074
Effectiveness of intervention
3 years 7 years 20 years
Man, 30 years 54,644 -25,164 -52,186
Woman, 30 years 55,441 -31,407 -61,140
Man, 50 years 65,552 -15,108 -39,813
Woman, 50 years 67,048 -21,215 -48,969
Man, 70 years 146,654 27,546 -13,294
Woman, 70 years 147,153 19,443 -24,960
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Page 10 of 13participants have higher health utilities than those who
do not participate [35,36]. Moreover, we assume that
the probability of moving from diabetes is the same
whether the person participates in the intervention or
not.
Herman et al [36] evaluated the lifetime cost-utility of
the DPP interventions in the United States and provided
a higher ICER of US$1,100/QALY gained. Reasons for
the higher ICER could be that the cost for the model
started with an increased diabetes risk, ie IGT, the life-
style intervention was higher, and it pertained to a life-
long duration. Caro et al [6] reported an ICER of CAS
$749/life year gained. This result is not comparable as
life years gained are not equivalent to QALYs gained.
Daziel et al [7] estimated a cost per QALY gained of
AU $1,880 [7]. However, the model was for 20 years.
The benefits of early intervention could thus be under-
estimated. Gillies et al [8] calculated a cost of £6242 for
screening for diabetes and impaired glucose tolerance
followed by lifestyle interventions. The higher cost for
one QALY gained could derive from a focus on screen-
ing and selection of individuals with at least one recog-
nised risk factor for T2D for their primary model
population [8]. Thus, the baseline population was con-
sidered to be at risk. Nevertheless, all the diabetes pre-
vention models indicate that lifestyle intervention is
cost-effective and this is consistent with our findings.
We found it difficult to compare utility weights from
different studies. The different methods used to extract
utility weights makes comparisons hard. In addition, no
study on utility weights of Germans with normal glucose
tolerance could be found.
We considered to externally validate the entire model
but realised that, as mentioned above, not all necessary
data a available yet. It can be possible in the future to
“validate” the model against high quality cohort studies
from Germany or Sweden or Spain, but such data does
not exist today. We have however checked our model
for consistency by including one-way and probabilistic
sensitivity analyses. What we try to develop is a more
“generic” model for some countries in Northern Europe,
and we think that information based on a country mix
is quite satisfaction for this purpose.
We considered to externally validate the entire model
but realised that, as mentioned above, not all necessary
data a available yet. It can be possible in the future to
“validate” the model against high quality cohort studies
from Germany or Sweden, but such data does not exist
today. We have however checked our model for consis-
tency by including one-way and probabilistic sensitivity
analyses. What we try to develop is a more “generic”
model for some countries in Northern Europe, and we
think that information based on a country mix is quite
satisfaction for this purpose.
Unanswered Questions and Further Research
We encourage further research on utility weights of nor-
mal glucose tolerance, impaired glucose tolerance and
type 2 diabetes mellitus. Multiple studies examine utility
weights of diabetes and states of complications. How-
ever, a further emphasis should be placed on the states
that precede diabetes and diabetes development. There
is a profound lack of studies on the utilities of IGT and
other prediabetic states.
As suggested by Roglic at al [25], the influence of
hyperglycemia on mortality is greater than the impact of
diabetes on mortality alone. Diabetes is a multi-faceted
disease with a higher risk of developing other diseases
such as heart disease and hypertension. Therefore, a
comprehensive study on mortality due to diabetes is
encouraged. We did not include the higher risk of dying
due to hyperglycemia because the model results were
inconsistent.
In addition, in order to draw more stable conclusions
about the cost-effectiveness of lifestyle intervention pro-
grammes, more studies on the transition probabilities
within interventions, programme resource use, and
long-term effects and compliance would be very
valuable.
These areas are encouraged for further research
because they are the parameters that yield the greatest
weaknesses in the model. Further investigation is needed
to improve the model.
Conclusions
Lifestyle interventions, as described in this article, are
cost-saving for men and women aged 30 or 50 years at
the start of the intervention and cost-effective for men
and women aged 70 years. Nonetheless, there is a high
degree of uncertainty around the ICERs. With the con-
servative approach adopted for this model, the long-
term effectiveness of the intervention could be underes-
timated. After further evaluation of lifestyle interven-
tions to prevent diabetes, this model should be updated
with effectiveness data that comes directly from the
intervention.
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